Clinical Application of Targeted Next Generation Sequencing for Colorectal Cancers
Promising targeted therapy and personalized medicine are making molecular profiling of tumours a priority. For colorectal cancer (CRC) patients, international guidelines made RAS (KRAS and NRAS) status a prerequisite for the use of anti-epidermal growth factor receptor agents (anti-EGFR). Daily, new...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2016-12-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/17/12/2117 |
id |
doaj-c18022484bc94b79bff3a9d6d7caac3b |
---|---|
record_format |
Article |
spelling |
doaj-c18022484bc94b79bff3a9d6d7caac3b2020-11-24T23:18:55ZengMDPI AGInternational Journal of Molecular Sciences1422-00672016-12-011712211710.3390/ijms17122117ijms17122117Clinical Application of Targeted Next Generation Sequencing for Colorectal CancersQuitterie Fontanges0Ricardo De Mendonca1Isabelle Salmon2Marie Le Mercier3Nicky D’Haene4Department of Pathology, Erasme Hospital, Université Libre de Bruxelles, 1070 Brussels, BelgiumDepartment of Pathology, Erasme Hospital, Université Libre de Bruxelles, 1070 Brussels, BelgiumDepartment of Pathology, Erasme Hospital, Université Libre de Bruxelles, 1070 Brussels, BelgiumDepartment of Pathology, Erasme Hospital, Université Libre de Bruxelles, 1070 Brussels, BelgiumDepartment of Pathology, Erasme Hospital, Université Libre de Bruxelles, 1070 Brussels, BelgiumPromising targeted therapy and personalized medicine are making molecular profiling of tumours a priority. For colorectal cancer (CRC) patients, international guidelines made RAS (KRAS and NRAS) status a prerequisite for the use of anti-epidermal growth factor receptor agents (anti-EGFR). Daily, new data emerge on the theranostic and prognostic role of molecular biomarkers, which is a strong incentive for a validated, sensitive and broadly available molecular screening test in order to implement and improve multi-modal therapy strategy and clinical trials. Next generation sequencing (NGS) has begun to supplant other technologies for genomic profiling. Targeted NGS is a method that allows parallel sequencing of thousands of short DNA sequences in a single test offering a cost-effective approach for detecting multiple genetic alterations with a minimum amount of DNA. In the present review, we collected data concerning the clinical application of NGS technology in the setting of colorectal cancer.http://www.mdpi.com/1422-0067/17/12/2117targeted next generation sequencingcolorectal cancerclinical application |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Quitterie Fontanges Ricardo De Mendonca Isabelle Salmon Marie Le Mercier Nicky D’Haene |
spellingShingle |
Quitterie Fontanges Ricardo De Mendonca Isabelle Salmon Marie Le Mercier Nicky D’Haene Clinical Application of Targeted Next Generation Sequencing for Colorectal Cancers International Journal of Molecular Sciences targeted next generation sequencing colorectal cancer clinical application |
author_facet |
Quitterie Fontanges Ricardo De Mendonca Isabelle Salmon Marie Le Mercier Nicky D’Haene |
author_sort |
Quitterie Fontanges |
title |
Clinical Application of Targeted Next Generation Sequencing for Colorectal Cancers |
title_short |
Clinical Application of Targeted Next Generation Sequencing for Colorectal Cancers |
title_full |
Clinical Application of Targeted Next Generation Sequencing for Colorectal Cancers |
title_fullStr |
Clinical Application of Targeted Next Generation Sequencing for Colorectal Cancers |
title_full_unstemmed |
Clinical Application of Targeted Next Generation Sequencing for Colorectal Cancers |
title_sort |
clinical application of targeted next generation sequencing for colorectal cancers |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2016-12-01 |
description |
Promising targeted therapy and personalized medicine are making molecular profiling of tumours a priority. For colorectal cancer (CRC) patients, international guidelines made RAS (KRAS and NRAS) status a prerequisite for the use of anti-epidermal growth factor receptor agents (anti-EGFR). Daily, new data emerge on the theranostic and prognostic role of molecular biomarkers, which is a strong incentive for a validated, sensitive and broadly available molecular screening test in order to implement and improve multi-modal therapy strategy and clinical trials. Next generation sequencing (NGS) has begun to supplant other technologies for genomic profiling. Targeted NGS is a method that allows parallel sequencing of thousands of short DNA sequences in a single test offering a cost-effective approach for detecting multiple genetic alterations with a minimum amount of DNA. In the present review, we collected data concerning the clinical application of NGS technology in the setting of colorectal cancer. |
topic |
targeted next generation sequencing colorectal cancer clinical application |
url |
http://www.mdpi.com/1422-0067/17/12/2117 |
work_keys_str_mv |
AT quitteriefontanges clinicalapplicationoftargetednextgenerationsequencingforcolorectalcancers AT ricardodemendonca clinicalapplicationoftargetednextgenerationsequencingforcolorectalcancers AT isabellesalmon clinicalapplicationoftargetednextgenerationsequencingforcolorectalcancers AT marielemercier clinicalapplicationoftargetednextgenerationsequencingforcolorectalcancers AT nickydhaene clinicalapplicationoftargetednextgenerationsequencingforcolorectalcancers |
_version_ |
1725579329476231168 |